RSS-Feed abonnieren
DOI: 10.1160/TH04-03-0154
Blood coagulation kinetics: high throughput method for real-time reaction monitoring
Publikationsverlauf
Received
12. März 2004
Accepted after resubmission
04. Juli 2004
Publikationsdatum:
06. Dezember 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/200404/lookinside/thumbnails/10-1160-th04-03-0154-1.jpg)
Summary
A high throughput 384-well plate assay of blood function in 60 μl reactions with the fluorogenic thrombin substrate, boc-VPR-MCA, allowed for real-time monitoring of coagulation under a diverse set of reaction conditions. Using recalcified, citrated whole blood diluted 3-fold with corn trypsin inhibitor (to block Factor XIIa), addition of 0 to 13.8 pM of tissue factor (TF) reduced the time of maximal rate of thrombin production (Tmax) from 45 min to 11 min. Over this range of TF,Tmax was reduced from 35 min to 6 min by co-addition of 10 nM convulxin to activate platelets via GPVI. The maximal rate of thrombin production at Tmax was not a function of exogenously-added TF, Va, or reVIIa, but increased 30% with added convulxin. Addition of 0.07 to 0.7 pM TF along with convulxin produced small, but detectable reductions in Tmax. Addition of up to 0.67 nM reVIIa reduced Tmax by up to 53% in the range of 0.7 to 7 pM TF. Interestingly, platelet factor 4 (2.7 μM) caused a prolongation of Tmax from 45 min to 78 min at 0 TF, while protamine (1.8 μM) reduced Tmax to 30 min at 0 TF. Finally, combinatorial reaction studies with exogenously-added ADP, histamine, fMLP, indomethacin, anti-CD18, and fibrinogen revealed no unusual synergies amongst the agents, but demonstrated a striking procoagulant activity of added fibrinogen, due to protease contaminants in the “purified” fibrinogen. This high throughput approach allowed automated profiling of blood (50 reactions/ml of blood) to generate large data sets for testing cellular-proteomic kinetic models, screening drug interactions, and potentially monitoring subtle changes in the functional phenotype of a patient blood sample.
-
References
- 1 Eerkes A, Shou WZ, Naidong W. Liquid/liquid extraction using 96-well plate format in conjunction with hydrophilic interaction liquid chromatography - tandem mass spectrometry method for the analysis of fluconazole in human plasma. J Pharm Biomed Anal 2003; 31: 917-28.
- 2 Xie F, Bruntlett CS, Zhu Y. et al. Good preclinical bioanalytical chemistry requires proper sampling from laboratory animals: automation of blood and microdialysis sampling improves the productivity of LC/MSMS. Anal Sci 2003; 19: 479-85.
- 3 Sugimoto M, Matsui H, Mizuno T. et al. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood 2003; 101: 915-20.
- 4 Klein B, Faridi A, von Tempelhoff GF. et al. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 2003; 108: 291-6.
- 5 Gosalia DN, Diamond SL. Printing chemical libraries on microarrays for fluid phase nanoliter reactions. Proc Natl Acad Sci U S A 2003; 100: 8721-6.
- 6 Hockin MF, Jones KC, Everse SJ. et al. A model for the stoichiometric regulation of blood coagulation. JBC 2002; 277: 18322-33.
- 7 Kuharsky AL, Fogelson AL. Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys J 2001; 80: 1050-74.
- 8 Bungay SD, Gentry PA, Gentry RD. A mathematical model of lipid-mediated thrombin generation. Math Med Biol 2003; 20: 105-29.
- 9 Doggett TA, Girdhar G, Lawshe A. Alterations in the intrinsic properties of the GPIbalphaVWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val. Blood 2003; 102: 152-60.
- 10 Laurenzi IJ, Diamond SL. Monte Carlo simulation of the heterotypic aggregation kinetics of platelets and neutrophils. Biophys J 1999; 77: 1733-46.
- 11 Butenas S, van’t CVeer, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. JBC 1997; 272: 21527-33.
- 12 Van’t CVeer, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. JBC 1997; 272: 4367-77.
- 13 Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
- 14 Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004; 02: 281-8.
- 15 Butenas S, Brummel KE, Branda RF. et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
- 16 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
- 17 Hemker HC, Giesen PL, Ramjee M. et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
- 18 Hemker HC, Giesen P, Al Dieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
- 19 Holmes MB, Schneider DJ, Hayes MG. et al. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000; 102: 2051-7.
- 20 Polgár J, Clemetson JM, Kehrel BE. et al. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. JBC 1997; 272: 13576-83.
- 21 Camire RM, Kalafatis M, Simioni P. et al. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood 1998; 91: 2818-29.
- 22 Tracy PB, Eide LL, Bowie EJ. et al. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982; 60: 59-63.
- 23 Lloyd JV, Joist JH. Recombinant factor VIIa: a universal hemostatic agent?. Curr Hematol Rep 2002; 01: 19-26.
- 24 Kaplan KL, Owen J. Plasma levels of betathromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202.
- 25 Bruins P, te HVelthuis, Eerenberg-Belmer AJ. et al. Heparin-protamine complexes and Creactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 2000; 84: 237-43.
- 26 Rauch U, Nemerson Y. Circulating tissue factor and thrombosis. Curr Opin Hematol 2000; 07: 273-7.
- 27 Goel MS, Diamond SL. Factor VIIa-mediated tenase function on activated platelets under flow. J Thromb Haemost 2004; 08: 1402-10.
- 28 Brummel KE, Paradis SG, Butenas S. et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
- 29 Lowe GD. The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol 2001; 06: 1-8.
- 30 Weitz JI. A novel approach to thrombin inhibition. Thromb Res 2003; 109: S17-22.